

### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application.

#### **Listing of Claims**

Claims 1-12 (cancelled).

Claim 13 (previously presented) The compound in the form of a crystalline salt which is 7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido-3-vinyl-cephem-4-carboxylic acid phosphate having an X-ray powder diffraction pattern substantially as that shown in Figure 1.

Claim 14 (cancelled).

Claim 15 (previously presented) The compound in the form of a crystalline salt which is 7-[2-(2-Aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid tosylate having an X-ray powder diffraction pattern substantially as that shown in Figure 3.

Claim 16 (previously presented) The compound in the form of a crystalline salt which is 7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid hydrogensulfate having an X-ray powder diffraction pattern substantially as that shown in Figure 4.

Claim 17 (previously presented) The compound in the form of a crystalline salt which is 7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid mesylate having an X-ray powder diffraction pattern substantially as that shown in Figure 5.

Claim 18 (previously presented) The compound in the form of a crystalline salt which is 7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid sulfate having an X-ray powder diffraction pattern substantially as that shown in Figure 6.

Claims 19-21 (cancelled).